Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-743 for Visual Function in Friedreich's Ataxia
NCT01728064Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Dec 2012
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vatiquinone in Friedreich's ataxia (FA) (3 arms), sponsored by PTC Therapeutics, Inc. Primary endpoint: Visual Function at 12 months. Started Dec 2012; status: completed.
02
Drugs
vatiquinone
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT01728064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01728064.